Reimagining Animal Health Research and Development
Boehringer Ingelheim has proudly announced the grand opening of its newest research and development facility, strategically located in Athens. This state-of-the-art establishment showcases the company's significant commitment to animal health innovation and advancements in veterinary medicine.
Significant Investment for Future Innovations
With an impressive capital investment exceeding $66 million, the expansion stands as a beacon of opportunity with 63 new jobs created. The facility now boasts an additional 63,000 square feet dedicated to administrative efforts alongside over 28,000 square feet designated for high-tech laboratory space. This ambitious expansion paves the way for revolutionary discoveries that will shape the future landscape of animal health.
Commitment to Animal Well-Being
“Our new research and development facility represents a pivotal moment in our ongoing dedication to animal health innovation,” said Peter Ploeger, U.S. Animal Health Country Managing Director. Every year, Boehringer Ingelheim allocates nearly 12% of its sales to develop and research new products aiming to elevate the health of animals, especially cherished pets.
A Hub of Collaboration and Research
This newly expanded facility stands as the largest R&D site for Boehringer Ingelheim in the United States and ranks third globally. With sustainability at its core, this facility houses the U.S. Global Innovation Hub, positioning it as Boehringer's leading venue for pet vaccine production and a crucial manufacturing site for poultry and wildlife vaccines.
Strengthening Local Economies
The Georgia Department of Economic Development has underscored the positive impacts of this facility on the local economy. Commissioner Pat Wilson stated that Boehringer Ingelheim's investment not only strengthens the local economy but also helps retain Georgia's well-educated, diverse workforce. This expansion is a testament to the significant role that Boehringer plays in fostering a robust ecosystem dedicated to life sciences and research.
Building Strong Community Partnerships
Deciding to expand in Athens was driven by various factors, including the proximity to USDA's National Poultry Research Center and the University of Georgia. Additionally, the partnership with Athens-Clarke County supports their Career Academy while initiating a pathway into biomanufacturing. These collaborations present unique opportunities for meaningful connections with talented individuals in the industry, all while supporting educational initiatives in animal health.
Leading the Charge in Poultry Health
“Being the nation’s foremost poultry producer places Georgia at the pinnacle of animal health and poultry disease research,” remarked Tyler Harper, Commissioner of the Georgia Department of Agriculture. The ongoing collaboration among the Georgia Department of Agriculture, the University of Georgia, and Boehringer Ingelheim is pivotal in ensuring the health of livestock and enhancing Georgia's food safety.
Shared Values and Commitment to Sustainability
Mayor Kelly Girtz of Athens-Clarke County highlighted the significance of this expansion in aligning with the community's core values, especially regarding sustainability and eco-friendly practices. The investment from Boehringer Ingelheim in local partnerships not only drives job growth but also amplifies the city's commitment to innovative and sustainable growth strategies.
This monumental expansion was made feasible through fruitful collaboration with several local organizations, including the Georgia Department of Economic Development, Invest Athens, Metro Atlanta Chamber, and Georgia Power.
About Boehringer Ingelheim Animal Health USA Inc.
Boehringer Ingelheim Animal Health is devoted to pioneering innovations for the prediction, prevention, and management of animal diseases. With a vast portfolio of innovative products and services offered across more than 150 countries, the company strives to enhance the health and welfare of companion animals and livestock alike.
As a globally recognized leader in the animal health arena, Boehringer Ingelheim adopts a long-range outlook. Understanding the interconnectedness of animal and human health, the company harnesses synergies between its Animal Health and Human Pharma sectors. Through this, they deliver profound value via innovation, thereby promoting better health for both animals and humans.
Frequently Asked Questions
What was the purpose of the newly opened facility?
The newly opened research and development facility aims to enhance animal health innovation and promote groundbreaking discoveries.
How much has Boehringer Ingelheim invested in this expansion?
Boehringer Ingelheim has made a capital investment of over $66 million in the new facility.
What types of jobs have been created due to this expansion?
The expansion has led to the creation of 63 new jobs, supporting local economic growth.
What is the significance of the partnerships formed in Athens?
The partnerships are designed to support education, innovation, and collaboration in animal health, particularly through programs in biomanufacturing.
How does this facility align with Boehringer Ingelheim's sustainability goals?
The facility embodies sustainability practices and eco-friendly initiatives which reflect Boehringer Ingelheim's commitment to innovative solutions in the community.
